RAVENQUEST BIOMED INC
OOTC:RVVQF0.00
USD
+0.00
(-90.00%)
ISIN
CA7543871080
CUSIP
754387108
Return %
Stock
S&P 500
1Y
0.00
14.20
3Y
0.00
81.12
5Y
-99.83
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- David Allen Cross
- Full Time Employees
- - -
- Sector
- Process industries
- Industry
- Agricultural commodities/Milling
- Address
- 580 Hornby Street Vancouver BC Canada V6E 2K3
- IPO Date
- Mar 5, 2018
- Website
- uvadhesiveglue.com
- Similar Companies
- Business
- RavenQuest BioMed Inc. (CSE:RQB, OTCQB:RVVQF) is a Canada-based diversified cannabis company focused on cannabis production, management services and consulting, and specialized research and development; it operates through segments including consulting business and cultivation and sale of medical cannabis. The company produces and sells cannabis products under the Lore Cannabis and Bloomera brand names; it provides integrated solutions such as growing and drying technologies, patient and genetic management systems, and security management solutions to companies in the cannabis industry. RavenQuest maintains licensed production facilities in Markham, Ontario, and Edmonton, Alberta, and emphasizes partnerships with Indigenous communities; it holds a research partnership with McGill University focused on cultivar recognition, plant stabilization, and yield maximization. Founded in 1987 and formerly known as Ravencrest Resources Inc. until its name change in September 2017, the company is headquartered in Vancouver, British Columbia, at 1177 West Hastings Street, Suite 2300. In recent developments, RavenQuest settled a patent infringement agreement with Roto-Gro International Limited in December 2024; the company was delisted from the Canadian Securities Exchange in May 2021 following a suspension in 2020, shifting its primary trading to OTC markets.